Abstract
We studied the effect of long-term treatment with the oral endothelin (ET) ETA antagonist 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut-2-enoate-sodium (PD 155080; PD) on right ventricular intracellular calcium (Ca2+i) handling and cardiac and pulmonary artery function in control rats and rats with monocrotaline (MCT)-induced right-heart hypertrophy. Rats were given an intraperitoneal injection of either saline (controls;n = 9) or MCT (50 mg/kg; n = 12), resulting in pulmonary hypertension-induced myocardial hypertrophy, or MCT followed by the daily administration of PD (50 mg/kg) for 9 weeks (n = 9). After 9 weeks, right ventricular pressure was measured, and the hearts were removed and perfused in vitro. Right ventricular function and Ca2+i transients were recorded simultaneously on a beat-to-beat basis using aequorin. Surviving animals in the MCT group (58%) developed significant hypertrophy and had 2-fold higher right ventricular pressure and a prolonged duration of isovolumic contraction that correlated with a similar prolongation of the Ca2+i transient, indicating a reduced rate of Ca2+ sequestration in hypertrophy (P< 0.05 versus control). In the PD group, all animals survived, and right ventricular pressure, diastolic relaxation, Ca2+transport kinetics, and peak systolic and end-diastolic wall stress were all normalized (P > 0.05 versus control); and pulmonary artery endothelial function was partly restored (P < 0.05 versus MCT and control groups). These results demonstrate for the first time that long-term ETAreceptor antagonism normalizes myocardial cytosolic Ca2+modulation, which may contribute to the antihypertrophic and cardioprotective effect of ETA receptor therapy in this model.
Footnotes
-
This work was supported by the Austrian Research Council (Fonds zur Förderung der wissenschaftlichen Forschung), projects 12934 and 13013 (to F.B.).
- Abbreviations:
- ET
- endothelin
- MCT
- monocrotaline
- PD and PD 155080
- 2-benzo[1,3]dioxol-5-yl-3-benzyl-4-(4-methoxy-phenyl-)-4-oxobut-2-enoate-sodium
- RVEDP
- right ventricular end-diastolic pressure
- RVDevP
- right ventricular developed pressure
- SNAP
- S-nitroso-N-acetylpenicillamine
- Ca2+i
- intracellular calcium
- NO
- nitric oxide
- Received July 9, 2001.
- Accepted October 23, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|